ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2307

Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome

Loukas chatzis1, Patrice Hemon2, Yvonne Scuiller3, Andreas Goules4, Divi Cornec5, Athanasios Tzioufas6 and Jacques-Olivier Pers3, 1Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 2LBAI, UMR1227, Univ Brest, INSERM, Brest, France, Paris, 3LBAI, UMR1227, Univ Brest, INSERM, Brest, France, Paris, France, 4GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, 5Service de Rhumatologie, CHU de Brest, Brest, France, 6LAIKO HOSPITAL, Athens, Greece

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Imaging mass cytometry (IMC) is a powerful high throughput technique that enables in-situ multiparametric analysis of a single fixed tissue section while preserving spatial architecture. Sjögren’s Disease (SjD), despite being one of the most common systemic autoimmune disorders, has still unclear pathogenetic mechanisms involved and no effective treatment.

In the present study, we aim to perform in-situ deep immunophenotype at a spatially resolved cellular level of the inflammatory infiltrates of minor salivary gland (MSG) biopsies of SjD patients at different stages of histologic involvement and Sjögren related mucosa-associated lymphoid tissue (MALT) lymphomas.

Methods: To fulfil the purpose of the study, we collected 5 MSG biopsies of Sicca controls [(Focus Score (FS):0-1, Anti – Ro/SSA (-), Anti-La/SSB (-)], five MSG biopsies from SjD patients with mild infiltrates [FS:1-2, Tarpley Score (TS):1], five with intermediate (FS:2-4, TS:2) and five with severe (FS: 4-12, TS: 3-4). In addition, we also collected four MSG biopsies of patients with SjD associated MALT lymphomas. All demographic, clinical and serologic patient’s data were available. Formalin-fixed, paraffin-embedded (FFPE) tissue sections were prepared and stained using a panel of 27 metal conjugated antibodies. Serial FFPE tissue sections were used for the 2 panels. The acquisition process was performed using the Hyperion™ (Fluidigm) system. Hyperion data processing and analysis necessitated the use of several software in a labour-intensive pipeline. For the segmentation of cells, a validated proprietary artificial intelligence software was exploited (Youpi).

Results: One hundred and four areas of interest (ROIs) were analyzed. Each ROI represented an inflammatory infiltrate, and a new stratification of the ROIs was created based on the number of T and B cells. Unsupervised clustering revealed the presence of 21 immune cell populations. The cellular subpopulations of inflammatory infiltrates differed between different regions in the same patient (Figure 1). The presence of CD45RBhigh Double Negative B Cells (CD27– IgD–) and Podoplanin+ Double Negative B Cells appears to characterize the progression of disease severity towards lymphoma. Additionally, Double Negative B Cells and CD45RB+ Switched Memory B cells (CD27+ IgD–) were shown to occur almost exclusively in SjD-related lymphoma (Figure 2).

Conclusion:  Advancing our knowledge on the target tissue, the variety of infiltrating cell subpopulations and their cell-to-cell interactions, previously limited by the low dimensionality of the histologic techniques available, might provide novel pathogenetic insights for the disease that can be targeted for the development of new treatment approaches for SjD.  The use of IMC highlighted the role of Double Negative B cells which may play an important role in the pathogenesis of the disease and serve as potential biomarkers.

Supporting image 1

Figure 1. Representative figure showing that the same patient can have infiltrates comprised by different cell subpopulations.

Supporting image 2

Figure 2. Results of the unsupervised analysis of the IMC (Hyperion) data unveiling 3 predominant immune cell subpopulations related to DN B cells, A. Phonograph gating plots of the 19 cell clusters is shown. B, C, D. The DN B cell subsets (01,06,19) seem to significantly increased in the SD3 group and lymphomas: FS (0_1) and Anti-Ro/SSA (-), SD1: FS (1_2), SD2: FS (2_3.5), SD3: FS (3.5_12), Lymphoma (MALT type).


Disclosures: L. chatzis: Pfizer, 2; P. Hemon: None; Y. Scuiller: None; A. Goules: AbbVie/Abbott, 6, Amgen, 1, Pfizer, 2; D. Cornec: None; A. Tzioufas: Pfizer, 2; J. Pers: None.

To cite this abstract in AMA style:

chatzis L, Hemon P, Scuiller Y, Goules A, Cornec D, Tzioufas A, Pers J. Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/deep-spatial-profiling-unveils-dominant-double-negative-b-cells-in-severe-forms-of-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deep-spatial-profiling-unveils-dominant-double-negative-b-cells-in-severe-forms-of-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology